S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
OTCMKTS:EVTCY

Evotec (EVTCY) Stock Forecast, Price & News

$11.67
+0.49 (+4.38%)
(As of 06/2/2023 ET)
Compare
Today's Range
$11.54
▼
$11.67
50-Day Range
$8.95
▼
$11.19
52-Week Range
$14.22
▼
$26.57
Volume
16,511 shs
Average Volume
2,407 shs
Market Capitalization
$3.85 billion
P/E Ratio
28.46
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest

EVTCY stock logo

About Evotec (OTCMKTS:EVTCY) Stock

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Receive EVTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVTCY Stock News Headlines

May 30, 2023 | finance.yahoo.com
Is There Now An Opportunity In Evotec SE (ETR:EVT)?
May 14, 2023 | finance.yahoo.com
Evotec SE (ETR:EVT) Shares Could Be 37% Below Their Intrinsic Value Estimate
June 3, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 13, 2023 | finanznachrichten.de
Evotec SE: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
May 12, 2023 | investing.com
Evotec SE ADR (EVO) Earnings Dates & Reports
May 10, 2023 | investing.com
Evotec SE ADR (EVO)
May 9, 2023 | finanznachrichten.de
Evotec SE: Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
April 10, 2023 | finance.yahoo.com
Evotec SE Provides Update on Cyber Attack
June 3, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
February 10, 2023 | finanznachrichten.de
Evotec SE: Evotec Receives € 150 m Loan from European Investment Bank
January 31, 2023 | markets.businessinsider.com
EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
December 22, 2022 | ca.finance.yahoo.com
With 47% ownership, Evotec SE (ETR:EVT) has piqued the interest of institutional investors
December 17, 2022 | finanznachrichten.de
Evotec SE: Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
September 21, 2022 | finanznachrichten.de
Evotec SE: Just - Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
September 20, 2022 | markets.businessinsider.com
Evotec: US Unit Gets $49.9 Mln Antibodies Contract From U.S. Department Of Defense
September 17, 2022 | finanznachrichten.de
Evotec SE: Evotec Initiates Ground-Breaking for New Biologics Facility J.POD Toulouse, France
August 13, 2022 | seekingalpha.com
Evotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call Transcript
August 11, 2022 | nasdaq.com
Evotec Slips To Loss In Q3, Revenues Rise; Lifts FY22 Revenue View, Backs Adj. EBITDA Forecast
August 11, 2022 | markets.businessinsider.com
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
August 11, 2022 | finance.yahoo.com
Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates
August 10, 2022 | finanznachrichten.de
Evotec SE: Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
May 11, 2022 | nasdaq.com
Evotec Q1 Adj. EBITDA Down, Revenues Up
April 12, 2022 | apnews.com
Evotec SE Fiscal Year 2021 Results: ‘Setting the Pace’ on the Data-Driven R&D Autobahn to Cures
April 12, 2022 | finanznachrichten.de
Evotec AG: Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
April 12, 2022 | seekingalpha.com
Evotec SE reports FY results
April 12, 2022 | nasdaq.com
Evotec FY21 Net Income Surges, Operating Result Down; Sees Higher Group Revenues In FY22
March 2, 2022 | markets.businessinsider.com
Evotec Confirms Goals Of Action Plan 2025
See More Headlines

EVTCY Price History

EVTCY Company Calendar

Today
6/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:EVTCY
CUSIP
N/A
CIK
1412558
Web
www.evotec.com
Phone
(494) 056-0810
Fax
49-40-5608-1222
Employees
3,572
Year Founded
1993

Profitability

EPS (Most Recent Fiscal Year)
$0.41
Trailing P/E Ratio
28.46
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$7.14 million
Net Margins
20.85%
Pretax Margin
23.90%
Return on Equity
16.02%
Return on Assets
7.81%

Debt

Debt-to-Equity Ratio
0.53
Current Ratio
2.57
Quick Ratio
2.50

Sales & Book Value

Annual Sales
$572.16 million
Price / Sales
6.74
Cash Flow
$0.11 per share
Price / Cash Flow
105.53
Book Value
$2.52 per share
Price / Book
4.63

Miscellaneous

Outstanding Shares
330,221,000
Free Float
N/A
Market Cap
$3.85 billion
Optionable
Not Optionable
Beta
0.98

Social Links


Key Executives

  • Werner Lanthaler
    Chief Executive Officer
  • Craig L. Johnstone
    Chief Operating Officer & Member-Management Board
  • Enno Spillner
    Chief Financial Officer
  • Cord E. Dohrmann
    Chief Scientific Officer
  • Volker Braun
    SVP, Head-Investor Relations & ESG

Key Competitors

View All Competitors













EVTCY Stock - Frequently Asked Questions

How have EVTCY shares performed in 2023?

Evotec's stock was trading at $8.09 at the start of the year. Since then, EVTCY stock has increased by 44.3% and is now trading at $11.67.
View the best growth stocks for 2023 here.

When did Evotec's stock split?

Evotec shares split on the morning of Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly minted shares were issued to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What is Evotec's stock symbol?

Evotec trades on the OTCMKTS under the ticker symbol "EVTCY."

How do I buy shares of Evotec?

Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evotec's stock price today?

One share of EVTCY stock can currently be purchased for approximately $11.67.

How much money does Evotec make?

Evotec (OTCMKTS:EVTCY) has a market capitalization of $3.85 billion and generates $572.16 million in revenue each year. The company earns $7.14 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Evotec have?

The company employs 3,572 workers across the globe.

Does Evotec have any subsidiaries?
The following companies are subsidiares of Evotec: Aptuit, Bionamics GmbH, Cell Culture Service GmbH, Central Glass Germany, Central Glass Germany. GmbH, Compound Focus, Cyprotex, Develogen AG, Euprotec, Evotec (India) Private Ltd, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, KINAXO Biotechnologies, Oxford Asymmetry International, RENOVIS, and Rigenerand Srl.
Read More
How can I contact Evotec?

Evotec's mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The official website for the company is www.evotec.com. The company can be reached via phone at (494) 056-0810, via email at investorrelations@evotec.com, or via fax at 49-40-5608-1222.

This page (OTCMKTS:EVTCY) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -